EUVIMEDEUVIMED entdecken
Multizentrische Studie

Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan

Ryosuke Yasuda, Katsuhiro Arai iD, Takahiro Kudo iD, Ryusuke Nambu iD, Tomoki Aomatsu, Naoki Abe, Toshihiko Kakiuchi iD, Kunio Hashimoto, Tsuyoshi Sogo, Michiko Takahashi, Yuri Etani, Ken Kato und 3 weitere

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16166 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Ryosuke Yasuda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Japanese Society for Pediatric Inflammatory Bowel Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Serum leucine‐rich alpha‐2 glycoprotein (LRG) and calprotectin have been studied as disease activity markers in adults with inflammatory bowel disease (IBD). We evaluated them in pediatric IBD patients.

Methods

Subjects under 17 years old undergoing care at 11 Japanese pediatric centers were retrospectively assigned to 3 groups representing Crohn's disease (CD), ulcerative colitis (UC), and normal controls (NC) with irritable bowel syndrome or no illness. Serum LRG and calprotectin were measured using commercial enzyme‐linked immunosorbent assay kits.

Results

We enrolled 173 subjects, including 74 with CD, 77 with UC, and 22 NC. Serum LRG concentrations in active CD (median, 200 μg/mL) were significantly greater than in remission (81 μg/mL; P < 0.001) or NC (69 μg/mL; P < 0.001). Serum calprotectin concentrations in active CD (2941 ng/mL) also were significantly greater than in remission (962 ng/mL; P < 0.05) or NC (872 ng/mL; P < 0.05). Serum LRG concentrations in active UC (134 μg/mL) were significantly greater than in remission (65 μg/mL; P < 0.01) but not significantly greater than in NC (69 μg/mL); serum calprotectin concentrations in active UC (1058 ng/mL) were not significantly different from those in remission (671 ng/mL) or NC (872 ng/mL). In receiver operating characteristic analyses of LRG, calprotectin, C‐reactive protein, and erythrocyte sedimentation rate for ability to distinguish active IBD from remission, CD and UC showed areas under receiver operating characteristic curves for LRG (0.77 and 0.70, respectively), exceeding those for calprotectin, C‐reactive protein, or erythrocyte sedimentation rate.

Conclusions

In pediatric IBD, serum LRG may better reflect disease activity than serum calprotectin, particularly in CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAdolescentAdultChildHumansBiomarkersC-Reactive ProteinFecesGlycoproteinsJapanLeucineLeukocyte L1 Antigen ComplexRetrospective Studies

Stichwörter der Autor:innen

biomarkerchildreninflammatory bowel diseaseserum calprotectinserum leucine-rich alpha-2 glycoprotein

Substanzen

BiomarkersC-Reactive ProteinGlycoproteinsLeucineLeukocyte L1 Antigen ComplexLRG1 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.
  • Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Pediatrics, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Infection and Immunology, Aichi Children's Health and Medical Center, Ohfu, Japan.

ORCID-Profile: Katsuhiro Arai, Takahiro Kudo, Ryusuke Nambu, Toshihiko Kakiuchi, Tatsuki Mizuochi

Förderung

  • Japanese Society for Pediatric Inflammatory Bowel Disease

Zitieren

APA

Yasuda, R., Arai, K., Kudo, T., Nambu, R., Aomatsu, T., Abe, N., Kakiuchi, T., Hashimoto, K., Sogo, T., Takahashi, M., Etani, Y., Kato, K., Yamashita, Y., Mitsuyama, K., & Mizuochi, T. (2023). Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16166

Vancouver

Yasuda R, Arai K, Kudo T, Nambu R, Aomatsu T, Abe N, et al. Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16166

BibTeX
@article{Yasuda2023,
  author = {Yasuda, Ryosuke and Arai, Katsuhiro and Kudo, Takahiro and Nambu, Ryusuke and Aomatsu, Tomoki and Abe, Naoki and Kakiuchi, Toshihiko and Hashimoto, Kunio and Sogo, Tsuyoshi and Takahashi, Michiko and Etani, Yuri and Kato, Ken and Yamashita, Yushiro and Mitsuyama, Keiichi and Mizuochi, Tatsuki},
  title = {Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16166}
}
Kostenlos starten →